Status:
COMPLETED
Prevalence of Primary Aldosteronism Among Hypertensive Patients With Atrial Arythmia
Lead Sponsor:
Centre Hospitalier de PAU
Conditions:
Primary Aldosteronism
Atrial Fibrillation
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Atrial arrhythmia is the most frequent cardiac arrhythmia. It is a source of significant morbidity. Hypertension is a major risk factor for atrial arrhythmias. Primary hyperaldosteronism (PA) is a co...
Detailed Description
Atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in France. It is a source of significant morbidity, a major deterioration in the quality of life and considera...
Eligibility Criteria
Inclusion
- Hypertensive patients aged of 18 to 65 years with atrial arrhythmia.
Exclusion
- BMI above 30
- Any situation where the discontinuation of treatments (including betablockers and diuretics) presents a risk according to the investigator
Key Trial Info
Start Date :
April 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04115280
Start Date
April 16 2020
End Date
July 26 2023
Last Update
August 22 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France
2
CH de Pau
Pau, France